How can the evaluation of genetic tests be enhanced? Lessons learned from the ACCE framework and evaluating genetic tests in the United Kingdom

Genetics in Medicine

Volumn 7, Issue 7, 2005, Pages 495-500

  Sanderson, Simon ^a,e   Zimmern, Ron ^b   Kroese, Mark ^b   Higgins, Julian ^b   Patch, Christine ^c   Emery, Jon ^d  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b Public Health Genetics Unit   (United Kingdom)

^c MRC BIOSTATISTICS UNIT   (United Kingdom)

^d UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^e UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Diagnosis; Evaluation; Genetic tests; Prediction

Indexed keywords

ARTICLE; BREAST CANCER; COLORECTAL CANCER; DIAGNOSTIC ACCURACY; GENETIC SCREENING; LEGAL ASPECT; MEDICAL ETHICS; METHODOLOGY; NATIONAL HEALTH SERVICE; PRACTICE GUIDELINE; PREDICTION; PUBLIC HEALTH; QUALITY CONTROL; SOCIAL ASPECT; UNITED KINGDOM; VALIDATION PROCESS;

GENETIC DISEASES, INBORN; GENETIC SCREENING; GREAT BRITAIN; HETEROZYGOTE; HETEROZYGOTE DETECTION; HUMANS;

EID: 26844559961     PISSN: 10983600     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.gim.0000179941.44494.73     Document Type: Article

References (41)

1. Haddow J, Palomaki G. ACCE: A Model Process for Evaluating Data on Emerging Genetic Tests. In Human Genome Epidemiology Khoury M, Little J, Burke W, eds. Oxford: Oxford University Press 2004:217-233.
2. Office of Genomics and Disease Prevention. A Model System for Collecting, Analyzing and Disseminating Information on Genetic Tests, http://www.cdc.gov/ genomics/activities/fbr.htm Accessed December 18, 2004.
3. Office of Genomics and Disease Prevention. Evaluation of Genomic Applications in Practice and Prevention, http://www.cdc.gov/genomics/gtesting/ egapp.htm. Accessed August 18,2005.
4. Department of Health. United Kingdom Genetic Testing Network, www.ukgtn.org. Accessed December 18, 2004.
5. Feinstein AR. Misguided efforts and future challenges for research on "diagnostic tests". J Epidemiol Community Health 2002;56:330-332.
6. Reid MC, Lachs MS, Feinstein AR. Use of methodological standards in diagnostic test research. Getting better but still not good. JAMA 1995;274:645-651.
7. Knottnerus JA, van Weel C, Muris JW. Evaluation of diagnostic procedures. BMJ 2002;324:477-480.
8. Gluud C, Gluud LL. Evidence based diagnostics. BMJ 2005;330:724-726.
9. Decks JJ. Systematic reviews in health care: Systematic reviews of evaluations of diagnostic and screening tests. BMJ 2001;323:157-162.
10. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM, et al. Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. Clin. Chem. Lab Med 2003;41:68-73.
11. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM et al. The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration. Ann. Intern. Med 2003;138:W1-12.
12. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000;283:2008-2012.
13. Evans D. Hierarchy of evidence: a framework for ranking evidence evaluating healthcare interventions. J. Clin. Nurs 2003;12:77-84.
14. Goel V. Appraising organised screening programmes for testing for genetic susceptibility to cancer. BMJ 2001;322:1174-1178.
15. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM et al. Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. Clin. Chem. Lab Med 2003;41:68-73.
16. Smith JE, Winkler RL, Fryback DG. The first positive: computing positive predictive value at the extremes. Ann. Intern. Med 2000;132:804-809.
17. Kroese M, Zimmern RL, Sanderson SP. Genetic Tests and their Evaluation: Can we answer the key questions? Genet. Med 2004;6:475-480.
18. Cystic Fibrosis Genetic Analysis Consortium. Cystic Fibrosis Mutation Database. http://www.genet.sickkids.on.ca/cftr/. Accessed August 18, 2005.
19. Palomaki GE, FitzSimmons SC, Haddow JE. Clinical sensitivity of prenatal screening for cystic fibrosis via CFTR carrier testing in a United States panethnic population. Genet. Med 2004;6:405-414.
20. Humphries SE, Gudnason V, Whittall R, Day IN. Single-strand conformation polymorphism analysis with high throughput modifications, and its use in mutation detection in familial hypercholesterolemia. International Federation of Clinical Chemistry Scientific Division: Committee on Molecular Biology Techniques. Clin. Chem 1997;43:427-435.
21. Valenstein PN. Evaluating diagnostic tests with imperfect standards. Am. J. Clin. Pathol 1990;93:252-258.
22. Alonzo TA, Pepe MS Using a combination of reference tests to assess the accuracy of a new diagnostic test. Stat. Med 1999;18:2987-3003.
23. Boyko EJ, Alderman BW, Baron AE. Reference test errors bias the evaluation of diagnostic tests for ischemic heart disease. J. Gen. Intern. Med 1988;3:476-481.
24. Burke W, Atkins D, Gwinn M, Guttmacher A, Haddow J, Lau J et al. Genetic test evaluation: information needs of clinicians, policy makers, and the public. Am. J. Epidemiol 2002;156:311-318.
25. Evans JP, Skrzynia C, Burke W. The complexities of predictive genetic testing. BMJ 2001;322:1052-1056.
26. Office of Genomics and Disease Prevention. ACCf Model System; draft genetic test reviews. http://www.cdc.gov/genomics/gtesting/ACCE/fbr.htm. Accessed August 18, 2005.
27. Jimenez C, Gagel RF. Genetic testing in endocrinology: lessons learned from experience with multiple endocrine neoplasia type 2 (MEN2). Growth Horm. IGF. Res. 2004;14 Suppl A:S150-157.
28. Watson MS, Cutting GR, Desnick RJ, Driscoll DA, Klinger K, Mennuti M et al. Cystic fibrosis population carrier screening: 2004 revision of American College of Medical Genetics mutation panel. Genet. Med 2004;6:387-391.
29. Marks D, Thorogood M, Neil HA, Humphries SE. A review on the diagnosis, natural history, and treatment of familial hypercholesterolaemia. Atherosclerosis 2003;168:1-14.
30. Mortality in treated heterozygous familial hypercholesterolaemia: implications for clinical management. Scientific Steering Committee on behalf of the Simon Broome Register Group. Atherosclerosis 1999;142:105-112.
31. Humphries SE, Galton D, Nicholls P. Genetic testing for familial hypercholesterolaemia: practical and ethical issues. QJM 1997;90:169-181.
32. Burke W, Zimmern RL. Ensuring the appropriate use of genetic tests. Nat. Rev. Genet 2004;5:955-959.
33. Burke W, Coughlin SS, Lee NC, Weed DL, Khoury MJ. Application of population screening principles to genetic screening for adult-onset conditions. Genet. Test 2001;5:201-211.
34. Godard B, Raeburn S, Pembrey M, Bobrow M, Farndon P, Ayme S. Genetic information and testing in insurance and employment: technical, social and ethical issues. Eur. J. Hum. Genet. 2003;11 Suppl2:S123-142.
35. Godard B, ten Kate L, Evers-Kiebooms G, Ayme S. Population genetic screening programmes: principles, techniques, practices, and policies. Eur. J. Hum. Genet. 2003;11 Suppl 2:549-87.
36. Dickenson DL. Can children and young people consent to be tested for adult onset genetic disorders? BMJ 1999;318:1063-1065.
37. Nuffield Council on Bioethics. Genetic Screening: Ethical Issues. 1993.
38. Parker M, Lucassen A. Working towards ethical management of genetic testing. Lancet 2002;360:1685-1688.
39. Zimmern RL. Genetic testing: a conceptual exploration. J. Med. Ethics 1999;25:151-156.
40. Burke W, Pinsky LE, Press NA. Categorizing genetic tests to identify their ethical, legal, and social implications. Am. J. Med. Genet 2001;106:233-240.
41. Advisory Committee on Genetic Testing Health Departments of the United Kingdom. Report on Genetic Testing for Late Onset Disorders. 1998.